This is a working overview of BPC 157, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-14. Anything still debated is marked as such rather than presented as settled.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
===== MeSH D08.811.913.696 – phosphotransferases (EC 2.7) ===== MeSH D08.811.913.696.175 – diphosphotransferases MeSH D08.811.913.696.175.300 – gtp pyrophosphokinase MeSH D08.811.913.696.175.650 – ribose-phosphate pyrophosphokinase MeSH D08.811.913.696.175.825 – thiamin pyrophosphokinase MeSH D08.811.913.696.310 – myosin type iii MeSH D08.811.913.696.445 – nucleotidyltransferases MeSH D08.811.913.696.445.035 – n-acylneuraminate cytidylyltransferase MeSH D08.811.913.696.445.184 – choline-phosphate cytidylyltransferase MeSH D08.811.913.696.445.308 – dna nucleotidyltransferases MeSH D08.811.913.696.445.308.300 – dna-directed dna polymerase MeSH D08.811.913.696.445.308.300.112 – dna polymerase beta MeSH D08.811.913.696.445.308.300.225 – dna polymerase i MeSH D08.811.913.696.445.308.300.230 – dna polymerase ii MeSH D08.811.913.696.445.308.300.235 – dna polymerase iii MeSH D08.811.913.696.445.308.300.750 – RNA-directed dna polymerase MeSH D08.811.913.696.445.308.300.750.375 – hiv-1 reverse transcriptase MeSH D08.811.913.696.445.308.300.750.750 – telomerase MeSH D08.811.913.696.445.308.300.875 – taq polymerase MeSH D08.811.913.696.445.308.325 – dna nucleotidylexotransferase MeSH D08.811.913.696.445.400 – glucose-1-phosphate adenylyltransferase MeSH D08.811.913.696.445.600 – nicotinamide-nucleotide adenylyltransferase MeSH D08.811.913.696.445.625 – 2',5'-oligoadenylate synthetase MeSH D08.811.913.696.445.650 – polynucleotide adenylyltransferase MeSH D08.811.913.696.445.692 – rec a recombinases MeSH D08.811.913.696.445.735 – rna nucleotidyltransferases MeSH D08.811.913.696.445.735.265 – dna, catalytic MeSH D08.811.913.696.445.735.270 – dna-directed rna polymerases MeSH D08.811.913.696.445.735.270.375 – dna primase MeSH D08.811.913.696.445.735.270.750 – rna polymerase i MeSH D08.811.913.696.445.735.270.762 – rna polymerase ii MeSH D08.811.913.696.445.735.270.775 – rna polymerase iii MeSH D08.811.913.696.445.735.270.887 – rna polymerase sigma 54 MeSH D08.811.913.696.445.735.532 – polyribonucleotide nucleotidyltransferase MeSH D08.811.913.696.445.735.630 – q beta replicase MeSH D08.811.913.696.445.735.720 – rna helicases MeSH D08.811.913.696.445.735.720.500 – eukaryotic initiation factor-4a MeSH D08.811.913.696.445.735.780 – rna replicase MeSH D08.811.913.696.445.735.917 – rna, ribosomal, self-splicing MeSH D08.811.913.696.445.800 – sulfate adenylyltransferase MeSH D08.811.913.696.445.825 – transposases MeSH D08.811.913.696.445.825.500 – hiv integrase MeSH D08.811.913.696.445.837 – transposon resolvases MeSH D08.811.913.696.445.850 – UDP-glucose—hexose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.875 – UTP—glucose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.900 – UTP—hexose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.950 – vdj recombinases MeSH D08.811.913.696.620 – phosphotransferases (alcohol group acceptor) MeSH D08.811.913.696.620.010 – adenosine kinase MeSH D08.811.913.696.620.155 – choline kinase MeSH D08.811.913.696.620.175 – deoxycytidine kinase MeSH D08.811.913.696.620.200 – diacylglycerol kinase MeSH D08.811.913.696.620.225 – fructokinases MeSH D08.811.913.696.620.225.850 – phosphofructokinases MeSH D08.811.913.696.620.225.850.500 – phosphofructokinase-1 MeSH D08.811.913.696.620.225.850.500.249 – phosphofructokinase-1, liver type MeSH D08.811.913.696.620.225.850.500.500 – phosphofructokinase-1, muscle type MeSH D08.811.913.696.620.225.850.500.750 – phosphofructokinase-1, type c MeSH D08.811.913.696.620.225.850.750 – phosphofructokinase-2 MeSH D08.811.913.696.620.240 – galactokinase MeSH D08.811.913.696.620.250 – glucokinase MeSH D08.811.913.696.620.275 – glycerol kinase MeSH D08.811.913.696.620.300 – hexokinase MeSH D08.811.913.696.620.475 – kanamycin kinase MeSH D08.811.913.696.620.525 – 1-phosphatidylinositol 3-kinase MeSH D08.811.913.696.620.550 – 1-phosphatidylinositol 4-kinase MeSH D08.811.913.696.620.650 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.913.696.620.680 – polynucleotide 5'-hydroxyl-kinase MeSH D08.811.913.696.620.682 – protein kinases MeSH D08.811.913.696.620.682.650 – phosphorylase kinase MeSH D08.811.913.696.620.682.700 – protein-serine-threonine kinases MeSH D08.811.913.696.620.682.700.062 – activin receptors MeSH D08.811.913.696.620.682.700.062.500 – activin receptors, type i MeSH D08.811.913.696.620.682.700.062.750 – activin receptors, type ii MeSH D08.811.913.696.620.682.700.109 – bone morphogenetic protein receptors MeSH D08.811.913.696.620.682.700.109.500 – bone morphogenetic protein receptors, type i MeSH D08.811.913.696.620.682.700.109.750 – bone morphogenetic protein receptors, type ii MeSH D08.811.913.696.620.682.700.125 – ca(2+)-calmodulin dependent protein kinase MeSH D08.811.913.696.620.682.700.125.500 – myosin-light-chain kinase MeSH D08.811.913.696.620.682.700.140 – casein kinases MeSH D08.811.913.696.620.682.700.140.300 – casein kinase i MeSH D08.811.913.696.620.682.700.140.300.100 – casein kinase ialpha MeSH D08.811.913.696.620.682.700.140.300.200 – casein kinase idelta MeSH D08.811.913.696.620.682.700.140.300.300 – casein kinase iepsilon MeSH D08.811.913.696.620.682.700.140.600 – casein kinase ii MeSH D08.811.913.696.620.682.700.150 – cyclic nucleotide-regulated protein kinases MeSH D08.811.913.696.620.682.700.150.125 – cyclic amp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.125.500 – beta-adrenergic-receptor kinase MeSH D08.811.913.696.620.682.700.150.150 – cyclic gmp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.575 – protamine kinase MeSH D08.811.913.696.620.682.700.200 – cyclin-dependent kinases MeSH D08.811.913.696.620.682.700.200.067 – cdc2-cdc28 kinases MeSH D08.811.913.696.620.682.700.200.067.249 – cdc2 protein kinase MeSH D08.811.913.696.620.682.700.200.067.500 – cdc28 protein kinase, s cerevisiae MeSH D08.811.913.696.620.682.700.200.067.875 – cyclin-dependent kinase 5 MeSH D08.811.913.696.620.682.700.200.067.900 – cyclin-dependent kinase 9 MeSH D08.811.913.696.620.682.700.200.323 – cyclin-dependent kinase 2 MeSH D08.811.913.696.620.682.700.200.451 – cyclin-dependent kinase 4 MeSH D08.811.913.696.620.682.700.200.515 – cyclin-dependent kinase 6 MeSH D08.811.913.696.620.682.700.200.580 – maturation-promoting factor MeSH D08.811.913.696.620.682.700.200.580.500 – cdc2 protein kinase MeSH D08.811.913.696.620.682.700.250 – dna-activated protein kinase MeSH D08.811.913.696.620.682.700.300 – eif-2 kinase MeSH D08.811.913.696.620.682.700.429 – glycogen synthase kinases MeSH D08.811.913.696.620.682.700.429.500 – glycogen synthase kinase 3 MeSH D08.811.913.696.620.682.700.494 – i-kappa B kinase MeSH D08.811.913.696.620.682.700.559 – map kinase kinase kinases MeSH D08.811.913.696.620.682.700.559.100 – map kinase kinase kinase 1 MeSH D08.811.913.696.620.682.700.559.200 – map kinase kinase kinase 2 MeSH D08.811.913.696.620.682.700.559.300 – map kinase kinase kinase 3 MeSH D08.811.913.696.620.682.700.559.400 – map kinase kinase kinase 4 MeSH D08.811.913.696.620.682.700.559.500 – map kinase kinase kinase 5 MeSH D08.811.913.696.620.682.700.559.800 – proto-oncogene proteins c-mos MeSH D08.811.913.696.620.682.700.559.842 – raf kinases MeSH D08.811.913.696.620.682.700.559.842.249 – oncogene proteins v-raf MeSH D08.811.913.696.620.682.700.559.842.374 – proto-oncogene proteins b-raf MeSH D08.811.913.696.620.682.700.559.842.500 – proto-oncogene proteins c-raf MeSH D08.811.913.696.620.682.700.565 – mitogen-activated protein kinase kinases MeSH D08.811.913.696.620.682.700.565.100 – map kinase kinase 1 MeSH D08.811.913.696.620.682.700.565.200 – map kinase kinase 2 MeSH D08.811.913.696.620.682.700.565.300 – map kinase kinase 3 MeSH D08.811.913.696.620.682.700.565.400 – map kinase kinase 4 MeSH D08.811.913.696.620.682.700.565.500 – map kinase kinase 5 MeSH D08.811.913.696.620.682.700.565.600 – map kinase kinase 6 MeSH D08.811.913.696.620.682.700.565.700 – map kinase kinase 7 MeSH D08.811.913.696.620.682.700.567 – mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.567.342 – extracellular signal-regulated map kinases MeSH D08.811.913.696.620.682.700.567.342.500 – mitogen-activated protein kinase 1 MeSH D08.811.913.696.620.682.700.567.342.750 – mitogen-activated protein kinase 3 MeSH D08.811.913.696.620.682.700.567.342.875 – mitogen-activated protein kinase 6 MeSH D08.811.913.696.620.682.700.567.342.937 – mitogen-activated protein kinase 7 MeSH D08.811.913.696.620.682.700.567.513 – jnk mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.567.513.500 – mitogen-activated protein kinase 8 MeSH D08.811.913.696.620.682.700.567.513.750 – mitogen-activated protein kinase 9 MeSH D08.811.913.696.620.682.700.567.513.800 – mitogen-activated protein kinase 10 MeSH D08.811.913.696.620.682.700.567.878 – p38 mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.586 – oncogene protein v-akt MeSH D08.811.913.696.620.682.700.606 – phytochrome a MeSH D08.811.913.696.620.682.700.646 – proline-directed protein kinases MeSH D08.811.913.696.620.682.700.646.500 – cyclin-dependent kinases MeSH D08.811.913.696.620.682.700.646.500.500 – cdc2-cdc28 kinases MeSH D08.811.913.696.620.682.700.646.500.500.500 – cyclin-dependent kinase 5 MeSH D08.811.913.696.620.682.700.646.500.750 – cyclin-dependent kinase 2 MeSH D08.811.913.696.620.682.700.646.500.875 – cyclin-dependent kinase 4 MeSH D08.811.913.696.620.682.700.646.500.937 – cyclin-dependent kinase 6 MeSH D08.811.913.696.620.682.700.646.625 – glycogen synthase kinase 3 MeSH D08.811.913.696.620.682.700.646.750 – mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.646.750.249 – extracellular signal-regulated map kinases MeSH D08.811.913.696.620.682.700.646.750.249.500 – mitogen-activated protein kinase 1 MeSH D08.811.913.696.620.682.700.646.750.249.750 – mitogen-activated protein kinase 3 MeSH D08.811.913.696.620.682.700.646.750.249.875 – mitogen-activated protein kinase 6 MeSH D08.811.913.696.620.682.700.646.750.249.937 – mitogen-activated protein kinase 7 MeSH D08.811.913.696.620.682.700.646.750.374 – jnk mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.646.750.374.500 – mitogen-activated protein kinase 8 MeSH D08.811.913.696.620.682.700.646.750.374.750 – mitogen-activated protein kinase 9 MeSH D08.811.913.696.620.682.700.646.750.374.800 – mitogen-activated protein kinase 10 MeSH D08.811.913.696.620.682.700.646.750.843 – p38 mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.725 – protein kinase C MeSH D08.811.913.696.620.682.700.725.100 – protein kinase C-alpha MeSH D08.811.913.696.620.682.700.725.400 – protein kinase C-delta MeSH D08.811.913.696.620.682.700.725.750 – protein kinase C-epsilon MeSH D08.811.913.696.620.682.700.755 – proto-oncogene proteins C-akt MeSH D08.811.913.696.620.682.700.759 – proto-oncogene proteins C-bcr MeSH D08.811.913.696.620.682.700.776 – proto-oncogene proteins C-pim-1 MeSH D08.811.913.696.620.682.700.827 – rhodopsin kinase MeSH D08.811.913.696.620.682.700.862 – ribosomal protein s6 kinases MeSH D08.811.913.696.620.682.700.862.249 – ribosomal protein s6 kinases, 70-kda MeSH D08.811.913.696.620.682.700.862.500 – ribosomal protein s6 kinases, 90-kda MeSH D08.811.913.696.620.682.725 – protein-tyrosine kinase MeSH D08.811.913.696.620.682.725.049 – focal adhesion protein-tyrosine kinases MeSH D08.811.913.696.620.682.725.049.500 – focal adhesion kinase 1 MeSH D08.811.913.696.620.682.725.049.750 – focal adhesion kinase 2 MeSH D08.811.913.696.620.682.725.200 – mitogen-activated protein kinase kinases MeSH D08.811.913.696.620.682.725.200.100 – map kinase kinase 1 MeSH D08.811.913.696.620.682.725.200.200 – map kinase kinase 2 MeSH D08.811.913.696.620.682.725.200.300 – map kinase kinase 3 MeSH D08.811.913.696.620.682.725.200.400 – map kinase kinase 4 MeSH D08.811.913.696.620.682.725.200.500 – map kinase kinase 5 MeSH D08.811.913.696.620.682.725.200.600 – map kinase kinase 6 MeSH D08.811.913.696.620.682.725.200.700 – map kinase kinase 7 MeSH D08.811.913.696.620.682.725.300 – proto-oncogene proteins c-fes MeSH D08.811.913.696.620.682.725.400 – receptor protein-tyrosine kinases MeSH D08.811.913.696.620.682.725.400.020 – fms-like tyrosine kinase 3 MeSH D08.811.913.696.620.682.725.400.024 – receptor, fibroblast growth factor, type 1 MeSH D08.811.913.696.620.682.725.400.037 – receptor, fibroblast growth factor, type 2 MeSH D08.811.913.696.620.682.725.400.043 – receptor, fibroblast growth factor, type 3 MeSH D08.811.913.696.620.682.725.400.046 – receptor, fibroblast growth factor, type 4 MeSH D08.811.913.696.620.682.725.400.050 – proto-oncogene proteins c-kit MeSH D08.811.913.696.620.682.725.400.075 – proto-oncogene proteins c-met MeSH D08.811.913.696.620.682.725.400.087 – proto-oncogene proteins c-ret MeSH D08.811.913.696.620.682.725.400.100 – receptor, epidermal growth factor MeSH D08.811.913.696.620.682.725.400.150 – receptor, erbb-2 MeSH D08.811.913.696.620.682.725.400.175 – receptor, erbb-3 MeSH D08.811.913.696.620.682.725.400.185 – receptor, igf type 1 MeSH D08.811.913.696.620.682.725.400.200 – receptor, insulin MeSH D08.811.913.696.620.682.725.400.500 – receptor, macrophage colony-stimulating factor MeSH D08.811.913.696.620.682.725.400.660 – receptor, trka MeSH D08.811.913.696.620.682.725.400.700 – receptor, trkb MeSH D08.811.913.696.620.682.725.400.800 – receptor, trkc MeSH D08.811.913.696.620.682.725.400.850 – receptors, eph family MeSH D08.811.913.696.620.682.725.400.850.050 – receptor, epha1 MeSH D08.811.913.696.620.682.725.400.850.100 – receptor, epha2 MeSH D08.811.913.696.620.682.725.400.850.150 – receptor, epha3 MeSH D08.811.913.696.620.682.725.400.850.200 – receptor, epha4 MeSH D08.811.913.696.620.682.725.400.850.250 – receptor, epha5 MeSH D08.811.913.696.620.682.725.400.850.300 – receptor, epha6 MeSH D08.811.913.696.620.682.725.400.850.400 – receptor, epha7 MeSH D08.811.913.696.620.682.725.400.850.500 – receptor, epha8 MeSH D08.811.913.696.620.682.725.400.850.600 – receptor, ephb1 MeSH D08.811.913.696.620.682.725.400.850.650 – receptor, ephb2 MeSH D08.811.913.696.620.682.725.400.850.700 – receptor, ephb3 MeSH D08.811.913.696.620.682.725.400.850.750 – receptor, ephb4 MeSH D08.811.913.696.620.682.725.400.850.800 – receptor, ephb5 MeSH D08.811.913.696.620.682.725.400.900 – receptors, platelet-derived growth factor MeSH D08.811.913.696.620.682.725.400.900.500 – receptor, platelet-derived growth factor alpha MeSH D08.811.913.696.620.682.725.400.900.750 – receptor, platelet-derived growth factor beta MeSH D08.811.913.696.620.682.725.400.925 – receptors, tie MeSH D08.811.913.696.620.682.725.400.925.249 – receptor, tie-1 MeSH D08.811.913.696.620.682.725.400.925.500 – receptor, tie-2 MeSH D08.811.913.696.620.682.725.400.950 – receptors, vascular endothelial growth factor MeSH D08.811.913.696.620.682.725.400.950.100 – vascular endothelial growth factor receptor-1 MeSH D08.811.913.696.620.682.725.400.950.200 – vascular endothelial growth factor receptor 2 MeSH D08.811.913.696.620.682.725.400.950.300 – vascular endothelial growth factor receptor-3 MeSH D08.811.913.696.620.682.725.500 – proto-oncogene proteins c-abl MeSH D08.811.913.696.620.682.725.800 – src-family kinases MeSH D08.811.913.696.620.682.725.800.315 – lymphocyte specific protein tyrosine kinase p56(lck) MeSH D08.811.913.696.620.682.725.800.472 – oncogene protein pp60(v-src) MeSH D08.811.913.696.620.682.725.800.551 – proto-oncogene proteins c-fyn MeSH D08.811.913.696.620.682.725.800.590 – proto-oncogene proteins c-hck MeSH D08.811.913.696.620.682.725.800.610 – proto-oncogene proteins c-yes MeSH D08.811.913.696.620.682.725.800.630 – proto-oncogene proteins pp60(c-src) MeSH D08.811.913.696.620.682.725.900 – zap-70 protein-tyrosine kinase MeSH D08.811.913.696.620.685 – pyridoxal kinase MeSH D08.811.913.696.620.695 – pyruvate kinase MeSH D08.811.913.696.620.750 – thymidine kinase MeSH D08.811.913.696.620.800 – uridine kinase MeSH D08.811.913.696.630 – phosphotransferases (carboxyl group acceptor) MeSH D08.811.913.696.630.025 – acetate kinase MeSH D08.811.913.696.630.050 – aspartate kinase MeSH D08.811.913.696.630.050.050 – aspartokinase homoserine dehydrogenase MeSH D08.811.913.696.630.700 – phosphoglycerate kinase MeSH D08.811.913.696.640 – phosphotransferases (nitrogenous group acceptor) MeSH D08.811.913.696.640.025 – arginine kinase MeSH D08.811.913.696.640.150 – creatine kinase MeSH D08.811.913.696.640.150.500 – creatine kinase, bb form MeSH D08.811.913.696.640.150.625 – creatine kinase, mb form MeSH D08.811.913.696.640.150.750 – creatine kinase, mitochondrial form MeSH D08.811.913.696.640.150.875 – creatine kinase, mm form MeSH D08.811.913.696.645 – phosphotransferases (paired acceptors) MeSH D08.811.913.696.645.700 – pyruvate, orthophosphate dikinase MeSH D08.811.913.696.650 – phosphotransferases (phosphate group acceptor) MeSH D08.811.913.696.650.025 – adenylate kinase MeSH D08.811.913.696.650.150 – atp synthetase complexes MeSH D08.811.913.696.650.150.500 – proton-translocating atpases MeSH D08.811.913.696.650.150.500.249 – bacterial proton-translocating atpases MeSH D08.811.913.696.650.150.500.500 – chloroplast proton-translocating atpases MeSH D08.811.913.696.650.150.500.750 – mitochondrial proton-translocating atpases MeSH D08.811.913.696.650.150.500.875 – vacuolar proton-translocating atpases MeSH D08.811.913.696.650.450 – guanylate kinase MeSH D08.811.913.696.650.550 – nucleoside-diphosphate kinase MeSH D08.811.913.696.650.575 – nucleoside-phosphate kinase MeSH D08.811.913.696.900 – transferases (other substituted phosphate groups) MeSH D08.811.913.696.900.074 – CDP-diacylglycerol—inositol 3-phosphatidyltransferase MeSH D08.811.913.696.900.150 – CDP-diacylglycerol—serine O-phosphatidyltransferase MeSH D08.811.913.696.900.200 – diacylglycerol cholinephosphotransferase MeSH D08.811.913.696.900.250 – ethanolaminephosphotransferase
Because of this fact, it has become common practice to establish the quality of NMR ensembles, by comparing it against the unique conformation determined by X-ray diffraction, for the same protein. However, the X-ray diffraction structure may not exist, and, since the proteins in solution are flexible molecules, a protein represented by a single structure may lead to underestimate the intrinsic variation of the atomic positions of a protein. A set of conformations, determined by NMR or X-ray crystallography may be a better representation of the experimental data of a protein than a unique conformation. The utility of a model will be given, at least in part, by the degree of accuracy and precision of the model. An accurate model with relatively poor precision could be useful to study the evolutionary relationships between the structures of a set of proteins, whereas the rational drug design requires both precise and accurate models. A model that is not accurate, regardless of the degree of precision with which it was obtained will not be very useful. Since protein structures are experimental models that can contain errors, it is very important to be able to detect these errors. The process aimed at the detection of errors is known as validation. There are several methods to validate structures, some are statistical like PROCHECK and WHAT IF while others are based on physical principles as CheShift, or a mixture of statistical and physics principles PSVS.
The low energy consumption, low maintenance and small size of LEDs has led to uses as status indicators and displays on a variety of equipment and installations. Large-area LED displays are used as stadium displays, dynamic decorative displays, and dynamic message signs on freeways. Thin, lightweight message displays are used at airports and railway stations, and as destination displays for trains, buses, trams, and ferries.
Sources: en.wikipedia.org
, not all individuals of the population have been removed, so some must remain susceptible. A driving force leading to the end of an epidemic is a decline in the number of infectious individuals. The epidemic does not typically end because of a complete lack of susceptible individuals. The role of both the basic reproduction number and the initial susceptibility are extremely important. In fact, upon rewriting the equation for infectious individuals as follows:
Prior to a law change in 2006, babies of non-citizens born in New Zealand were entitled to New Zealand citizenship. 18 February: Government Statistician Mark Sowden confirms he will resign on 30 March after an inquiry by the Public Service Commission into data breach allegations at Manurewa Marae in 2023 criticised Statistics New Zealand's handling of personal information and management of conflicts of interest. Torrential rain leads to flash flooding in parts of Otago including Beaumont. 19 February: The New Zealand Government establishes a NZ$2 million dual purpose fund to honour children who died in care and were buried in unmarked graves. A group of abuse survivors picket the Accident Compensation Corporation's Christchurch office, demanding the company reform eligibility coverage policies for abuse survivors. 20 February: Associate Immigration Minister Chris Penk uses his discretionary powers to grant Davan Kumar a residency visa but upholds the deportation order against his overstayer parents. Australian and New Zealand Defence Ministers Richard Marles and Judith Collins confirm that the Australian and New Zealand Defence Forces are monitoring three Chinese warships that are sailing through international waters near Sydney. New Zealand Media and Entertainment confirms plans to layoff several senior reporters and create a new Free ad-supported streaming television (FAST) channel. 21 February: Flights between Australia and New Zealand are diverted after the Chinese Navy conducts live fire drills using warships 340 nautical miles east of Sydney, in international waters.
Neurologic examination A systematic clinical assessment of motor, sensory, reflex, and cognitive function to diagnose disorders of the nervous system. Neuromodulation The physiological process by which a given neuron uses chemicals to regulate diverse populations of neurons. May be endogenous (e.g., dopamine) or externally applied via electrical stimulation. Neuromodulator A substance that alters the effectiveness of synaptic transmission without directly causing excitatory or inhibitory postsynaptic potentials. Examples include serotonin, acetylcholine, and norepinephrine. Neuron A specialized cell in the nervous system that transmits electrical and chemical signals. Composed of a cell body, axon, and dendrites. Neuropil A dense network of interwoven nerve fibers, dendrites, and glial processes where synaptic activity occurs, commonly found in the gray matter of the brain. Neuroplasticity See neural plasticity. Neuroprosthetics A field that develops devices that interface with the nervous system to restore lost function, such as cochlear implants or brain–computer interfaces. Neuropsychiatry A medical field combining aspects of neurology and psychiatry to treat disorders with both neurological and psychiatric components, such as OCD or Tourette syndrome. Neuropsychology The study of the relationship between brain function and behavior, often using cognitive testing and brain imaging to assess individuals with brain injury or disease.
Such programs typically relate to youth, schools, public health, and social assistance. Second, Article 28(2) of the Basic Law guarantees the municipalities "the right to regulate on their own responsibility all the affairs of the local community within the limits set by law". Under this broad statement of competence, local governments can justify a wide range of activities. For instance, many municipalities develop and expand the economic infrastructure of their communities through the development of industrial trading estates. Local authorities foster cultural activities by supporting local artists, building arts centres, and by holding fairs. Local government also provides public utilities, such as gas and electricity, as well as public transportation. The majority of the funding for municipalities is provided by higher levels of government rather than from taxes raised and collected directly by themselves. In five of the German states, there are unincorporated areas, in many cases unpopulated forest and mountain areas, but also four Bavarian lakes that are not part of any municipality. As of 1 January 2005, there were 246 such areas, with a total area of 4167.66 km2 or 1.2% of the total area of Germany. Only four unincorporated areas are populated, with a total population of around 2,000. The table below provides an overview.
Sources: en.wikipedia.org
After extensive testing, which can take up to six years, the new medicine is ready for marketing and selling. Because of these long timescales and the fact that only one out of every 5000 potential new medicines will ever reach the open market, this is an expensive way of doing things, often costing over 1 USD billion per drug. To recoup this outlay, pharmaceutical companies may do a number of things:
The tyrocidine synthetases TycA, TycB, and TycC are encoded on the tyrocidine operon. This consists of the three genes encoding for the three synthetases as well as three additional open reading frames (ORFs). These ORFs, labeled as TycD, TycE, and TycF are downstream of the three synthetase genes (see figure 2). TycD &TycE have the highest similarity to members of the ATP-binding cassette (ABC) transporter family which aid in the transport of substrates across a membrane. It has been suggested that the tandem transporters play a role in conferring resistance in the producer cell through tyrocidine secretion. TycF has been identified as a thioesterase (TE) and is similar to other TEs in bacterial operons used for encoding peptide synthetases. However, the precise function of these TEs remains unknown. The size of the peptide synthetases corresponds to the amount of activation they carry out. TycA is the smallest and activates a single amino acid from one module, TycB is intermediate in size and activates 3 amino acids with 3 modules, and TycC is the largest and activates 6 amino acids with 6 modules (See figure 3).
== Procedure == The exact methods of this procedure are not standardized and vary considerably, for example the exact number and locations of the injections and the volume of the injected material. Before the operation, antibiotic prophylaxis may be given. The rectum is prepared with a phosphate enema at least 2 hours before the procedure. The procedure can be carried out under local anesthetic on an out patient basis, or with caudal epidural anesthesia, or with intravenous sedation, or under general anesthesia. Ultrasound guidance may be used during the injections, which is sometimes reported as being more effective than the surgeon simply palpating (feeling) and looking where to inject. The site of the bulking material can be inter-sphincteric (in the space between the IAS and the EAS), submucosal injections (under the mucosal layer, usually just above the dentate line), or within the IAS itself. Injection of the material can be by the different routes: transanal route, trans-sphincteric, intersphincteric, perianal route (going through the muscle complex) or transcutaneous route. As such, there are several different variations of injection location and route:
== Advantages == SHIM offers several advantages for live cell and tissue imaging. SHG does not involve the excitation of molecules like other techniques such as fluorescence microscopy therefore, the molecules shouldn't suffer the effects of phototoxicity or photobleaching. Also, since many biological structures produce strong SHG signals, the labeling of molecules with exogenous probes is not required which can also alter the way a biological system functions. By using near infrared wavelengths for the incident light, SHIM has the ability to construct three-dimensional images of specimens by imaging deeper into thick tissues.
=== Polypeptides === The convention for a polypeptide is to list its constituent amino acid residues as they occur from the amino terminus to the carboxylic acid terminus. The amino acid residues are always joined by peptide bonds. Protein, though used colloquially to refer to any polypeptide, refers to larger or fully functional forms and can consist of several polypeptide chains as well as single chains. Proteins can also be modified to include non-peptide components, such as saccharide chains and lipids.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.